Filament Health Corp. announced that it successfully completed an export of PEX010, the Company's botanical psilocybin drug candidate, to Perth, Western Australia. The shipment is believed to be the first botanical psilocybin to be exported to Australia and was received by Reset Mind Sciences Ltd. a psychedelic-focused subsidiary of Little Green Pharma, a biotechnology company dedicated to developing natural quality medicines to help those living with chronic conditions.

Reset will use Filament's drug product for research purposes. Since July 1, 2023, authorised psychiatrists in Australia have been able to prescribe psilocybin for treatment-resistant depression. Reset is progressing its GMP licence application to manufacture psilocybin products for human consumption from botanically sourced psilocybin while the industry awaits publication of the Australian Therapeutic Goods Administration's Therapeutic Goods Order governing psilocybin production in Australia.